Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05369_nanopub.RAnQPGxIq6G9gxiQ3A_NOqTqmDdbxtwzK8_B7NoWzrSWs#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05369 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05369 label "HZT-501 [drugbank:DB05369]" assertion.
- drugbank:DB05369 seeAlso DB05369 assertion.
- drugbank:DB05369 description "HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine." assertion.
- drugbank:DB05369 identifier "drugbank:DB05369" assertion.
- drugbank:DB05369 title "HZT-501" assertion.
- drugbank:DB05369 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05369 drugbank_vocabulary:drugbank-id "DB05369" assertion.
- drugbank:DB05369 bio2rdf_vocabulary:x-identifiers.org DB05369 assertion.
- drugbank:DB05369 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05369" assertion.
- drugbank:DB05369 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05369 bio2rdf_vocabulary:identifier "DB05369" assertion.